Beigene (NASDAQ:BGNE) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a research note issued on Wednesday.

Several other research firms also recently issued reports on BGNE. Zacks Investment Research upgraded Beigene from a “sell” rating to a “hold” rating in a research note on Wednesday, June 6th. ValuEngine upgraded Beigene from a “hold” rating to a “buy” rating in a research note on Friday, June 1st. Maxim Group increased their target price on Beigene from $200.00 to $225.00 and gave the company a “buy” rating in a research note on Friday, May 18th. Piper Jaffray Companies set a $200.00 target price on Beigene and gave the company a “buy” rating in a research note on Monday, July 23rd. Finally, Credit Suisse Group began coverage on Beigene in a research note on Monday, May 14th. They set an “outperform” rating for the company. Two equities research analysts have rated the stock with a sell rating, one has issued a hold rating and seven have issued a buy rating to the company. Beigene presently has a consensus rating of “Buy” and an average target price of $187.50.

BGNE opened at $159.28 on Wednesday. The stock has a market cap of $8.89 billion, a PE ratio of -71.43 and a beta of 0.78. Beigene has a 52-week low of $65.58 and a 52-week high of $220.10. The company has a quick ratio of 8.10, a current ratio of 8.14 and a debt-to-equity ratio of 0.16.

Beigene (NASDAQ:BGNE) last released its quarterly earnings results on Thursday, August 9th. The company reported ($2.92) earnings per share (EPS) for the quarter, missing the consensus estimate of ($2.12) by ($0.80). The company had revenue of $52.80 million for the quarter, compared to the consensus estimate of $22.53 million. Beigene had a negative return on equity of 24.14% and a negative net margin of 75.19%. The business’s revenue was up 5279999900.0% compared to the same quarter last year. During the same quarter last year, the company posted ($1.52) EPS. equities research analysts forecast that Beigene will post -9.09 earnings per share for the current year.

In related news, Director Xiaodong Wang sold 3,449 shares of the stock in a transaction that occurred on Monday, August 13th. The stock was sold at an average price of $158.77, for a total transaction of $547,597.73. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO John Oyler sold 2,550 shares of the stock in a transaction that occurred on Monday, July 16th. The shares were sold at an average price of $164.12, for a total value of $418,506.00. The disclosure for this sale can be found here. 14.10% of the stock is owned by corporate insiders.

A number of large investors have recently made changes to their positions in BGNE. Geode Capital Management LLC boosted its stake in Beigene by 18.4% during the 4th quarter. Geode Capital Management LLC now owns 17,390 shares of the company’s stock valued at $1,699,000 after purchasing an additional 2,706 shares during the period. Wells Fargo & Company MN lifted its position in shares of Beigene by 23,414.5% in the 1st quarter. Wells Fargo & Company MN now owns 43,737 shares of the company’s stock worth $7,348,000 after acquiring an additional 43,551 shares during the period. Daiwa Securities Group Inc. bought a new stake in shares of Beigene in the 1st quarter worth approximately $942,000. Ariose Capital Management Ltd bought a new stake in shares of Beigene in the 1st quarter worth approximately $15,469,000. Finally, Alps Advisors Inc. lifted its position in shares of Beigene by 10.5% in the 1st quarter. Alps Advisors Inc. now owns 55,678 shares of the company’s stock worth $9,354,000 after acquiring an additional 5,296 shares during the period. Hedge funds and other institutional investors own 67.32% of the company’s stock.

Beigene Company Profile

BeiGene, Ltd., a clinical-stage biopharmaceutical company, develops and commercializes molecularly-targeted and immuno-oncology drugs for the treatment of cancer. Its commercial products include ABRAXANE, a solvent-free chemotherapy product for the treatment of breast, non-small cell lung, pancreatic, and gastric cancer; REVLIMID, an oral immunomodulatory drug for the treatment of multiple myeloma in combination with dexamethasone; and VIDAZA, a pyrimidine nucleoside analog for the treatment of intermediate-2 and high-risk myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia with 20% to 30% blasts and multi-lineage dysplasia.

Featured Article: How to Track your Portfolio in Google Finance

Analyst Recommendations for Beigene (NASDAQ:BGNE)

Receive News & Ratings for Beigene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Beigene and related companies with MarketBeat.com's FREE daily email newsletter.